A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.

Inclusion Criteria: * Age \> 18 years. * Advanced cancer potentially sensitive to vinorelbine: * Breast cancer. * Stage 3 or 4 non-small cell lung cancer. * Non-Hodgkins lymphoma. * Cancer of other histologic type, sensitive to vinca alkaloids. * Rare tumor type with no standard treatment, for which single agent vinorelbine is appropriate therapy. * Failure of standard treatment(s) of the tumor. * Life expectancy of at least three months. * ECOG performance level 0-2 or Karnofsky score 100-70. * Hematological and serum chemistry results with defined ranges. * Willingness and ability to provide written informed consent. Exclusion Criteria: * Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no use of reliable contraception, at baseline. A postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months. * Previous treatment with vinorelbine or mitomycin. * Any history suggesting or demonstrating resistance to, lack of response to, or intolerance of any prior vinca alkaloid treatment. * Active infection. * Prior anticancer therapy completed within four weeks prior to the first day of study treatment. * Failure to have recovered from any toxicity of previous cancer treatment (patients with alopecia will not be excluded). * Participation in another experimental drug study within four weeks prior to the first day of study treatment. * Requirement for any concomitant chemotherapeutic agent other than the study medication. * Any investigator judgment that the individual would not be an appropriate study subject.